For US residents only.

Combined Inhibition of MAPK and PD-1 in Melanoma

In BRAF+ Melanoma, Targeting the MAPK Pathway Can Alter the Tumor Microenvironment in a Way That Could Be Synergistic When Combined With PD-1 Blockade.

For additional information on melanoma clinical trials, please click here.

2/20 M-GON-1226454